◀ Back to MAPK15

MAP2K1 — MAPK15

Text-mined interactions from Literome

Hashimoto et al., Life Sci 1999 : To this end, we examined changes in cellular morphology and MAPK activation in NE-stimulated BEC monolayer, and the effect of PD 98059 as the specific inhibitor for MAPK kinase-1 ( MEK-1 , the upstream regulator of MAPK ) on NE-induced changes in cellular morphology and MAPK activation
Gire et al., Oncogene 1999 : Conversely, selective activation of MAPK by a constitutively-active MAPKK1 mutant failed to mimic the action of Ras and, although this was achievable with activated Raf, micro-injection of anti-ras antibodies showed that this still required endogenous wild-type Ras function
Martel-Pelletier et al., Arthritis Rheum 1999 (Osteoarthritis) : Within minutes, IL-17 induced the phosphorylation of mitogen activated protein kinase kinase-1/2 ( MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the activation of mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 ) ... Within minutes, IL-17 induced the phosphorylation of mitogen activated protein kinase kinase-1/2 ( MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the activation of mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 )
McDuffie et al., J Cardiovasc Pharmacol 2000 : The agonist stimulated phosphorylation of MAPK was blocked by the 5-HT1b-receptor antagonist isamoltane ( 0.01-10 p3M ) and the MEK-1 inhibitor PD 098059 ( [ 2- ( 2'-amino-3'-methoxy-phenyl ) -oxanaphthalen-4-one ] ; 0.01-10 microM¿
Newton et al., Br J Pharmacol 2000 : We have therefore used these cells to examine the effect of the selective mitogen activated protein ( MAP ) kinase inhibitors ; PD098059, a mitogen activated and extracellular regulated kinase kinase ( MEK) 1 inhibitor , UO126, a dual MEK1 & MEK2 inhibitor, and SB203580, a p38 MAP kinase inhibitor in the IL-1beta dependent release of PGE ( 2 )
Learish et al., Brain Res Dev Brain Res 2000 : These data provide evidence that activation of MAPK by MEK1 is important for the proliferation of NP cells
Hayashi et al., Eur Respir J 2000 : Lung fibroblasts were stimulated with BK in the presence or in the absence of PD98059, a specific MAPK/ERK kinase-1 inhibitor, or SB203580, a specific p38 MAPK inhibitor , and IL-6 or IL-8 production and their gene expression was examined
Hayashi et al., Hepatology 2000 : Moreover, the MAPK/ERK activation by HCV core protein was blocked in the presence of the specific MEK1 inhibitor, PD98059
Tu et al., J Biomed Sci 2001 (Carcinoma, Hepatocellular) : On the other hand, PD98059, a specific inhibitor of mitogen activated protein kinase kinase , blocks TPA induced MAPK activation but has no effect on TPA induced tyrosine phosphorylation
Choi et al., Cancer Res 2001 (Glioblastoma...) : Herein, we demonstrate that : ( a ) stimulation with agonistic anti-Fas monoclonal antibody CH-11 and human recombinant soluble Fas ligand induces expression of the CC chemokine MCP-1 and the CXC chemokine interleukin-8 by human glioma cell lines at the mRNA and protein levels in a dose- and time dependent manner ; ( b ) selective pharmacological inhibitors of MEK1 ( U0126 and PD98059 ) and p38 mitogen activated protein kinase ( MAPK ) ( SB202190 ) suppress Fas mediated chemokine expression in a dose dependent manner ; ( c ) Fas ligation on human glioma cells leads to activation of both extracellular signal regulated kinases ERK1/ERK2 and p38 MAPK ; and ( d ) GBM samples express higher levels of Fas compared with normal control brain, which correlates with increased interleukin 8 expression
Tseng et al., Biochem Biophys Res Commun 2001 : To determine the involvement of MEK1-p42/p44 MAPK pathway in mediating DAB2 gene expression, we have performed the following experiments and found that ( i ) there was sustained activation of p42/p44 MAPK , but not p38 MAPK, upon K562 cells differentiation ; ( ii ) application of MEK1 inhibitor U0126 reduced the expression of DAB2 protein, mRNA and promoter activity, as well as cell differentiation ; ( iii ) constitutively active MEK1 increased DAB2 promoter activity ; and ( iv ) dominant negative ERK2 abolished constitutively active MEK1 induced DAB2 promoter activity
Iwata et al., J Biol Chem 2001 (MAP Kinase Signaling System) : Transfection of constitutively active MEK-1 resulted in MAPK phosphorylation in alpha-synuclein expressing cells and improved cell viability even under reduced serum conditions
Boyd et al., Neuropharmacology 2002 : Using two structurally distinct inhibitors of the activation of MEK1 ( mitogen activated protein ( MAP) kinase kinase 1 ), PD 98059 and U 0126, we have shown that the MAP kinase signalling cascade does not appear to underlie muscarinic inhibition of IK ( SO ), recorded using whole-cell patch-clamp methods
Tao et al., Biochem J 2002 : We present data showing that overexpression of the serine threonine kinase, mitogen activated protein kinase/extracellular-signal regulated kinase kinase kinase-1 ( MEKK1 ), but not nuclear factor-kappa B inducing kinase, or MAP kinase/ERK kinase-1 (MEK1) , can significantly increase the level of CD28RE/AP1-driven luciferase ( Luc ) reporter gene expression in Jurkat E6-1 cells
McKinstry et al., Cancer Biol Ther 2002 (Breast Neoplasms...) : Inhibition of MEK1/2 caused modest reductions in basal MAPK activity and transiently suppressed UCN-01 stimulated MAPK activity below that of MEK1/2 inhibitor alone
Huang et al., Biochem Biophys Res Commun 2003 : MAP3Ks are components of a three tiered protein kinase pathway in which a MAP3K phosphorylates and activates a mitogen activated protein kinase kinase ( MAP2K ), which in turn activates a mitogen activated protein kinase ( MAPK )
Yu et al., Oncogene 2004 (Leukemia) : These events were accompanied by the caspase independent downregulation of Raf-1, inactivation of MEK1/2 , ERK, Akt, p70S6K, dephosphorylation of GSK-3, and activation of c-Jun-N-terminal kinase (JNK) and p38 MAPK
Yue et al., Curr Biol 2004 : The MAPK activator MEK1 is required for mitotic activation of p42 MAPK in Xenopus egg extracts ; however, the identity of the kinase that activates MEK1 is unknown
Zhang et al., Arterioscler Thromb Vasc Biol 2005 (Vasculitis) : In contrast, mitogen activated protein kinase kinase-1 ( MEK1 ) inhibition ( dominant negative MEK1 adenovirus or inhibitor U0126 ) suppressed Ang II-induced NF-kappaB promoter activity, NF-kappaB DNA binding activity, p65 phosphorylation, and led to 70 % reduction in IL-6 transcription/production
Minelli et al., Peptides 2006 : It greatly enhances the phosphorylation of hsp27, alpha-B-crystallin, Cdc2, and p-38 MAPK , whereas it decreases the phosphorylation of MEK1 , Cav 2, GSK3a, PKB/Akt, PKCdelta, PKCgamma, and Erk2
Mukherjee et al., Carcinogenesis 2006 (Chromosomal Instability) : Activation of both ERKs and p38 MAPK by BPDE and attenuation of BPDE induced p53 accumulation by U0126 or SB202190, specific inhibitor of MEK1/2 or p38 MAPK, indicate the role of ERKs and p38 MAPK in p53 accumulation
Lee et al., J Cell Physiol 2006 : TNF-alpha enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK , p38, and JNK were significantly attenuated by inhibitors of MEK1/2 ( U0126 ), p38 ( SB202190 ), and JNK ( SP600125 )
Chien et al., Biochem Biophys Res Commun 2006 (Lung Neoplasms) : SB203580, a p38 MAPK inhibitor, but not PD098059 and SP600125, specific inhibitor of MKK1 and selective inhibitor of JNK, respectively, suppressed COX-2 expression
Wu et al., Cell Microbiol 2006 (MAP Kinase Signaling System) : Our results showed that phosphorylated mitogen activated protein kinase ( MAPK ) kinase ( MEK) 1/2, p44/p42 MAPK and p90 ribosomal S6 kinase (p90RSK) were observed and this pathway was inhibited by MEK1/2 inhibitors U0126 and PD98059
Klegeris et al., FASEB J 2006 (Astrocytoma...) : It is also attenuated by PD 98059, an inhibitor of the MAPK/extracellular regulated kinase kinase MEK1/2 , SP 600125, an inhibitor of c-Jun N-terminal kinase (JNK), and SB 202190, an inhibitor of p38 MAPK
Bajpai et al., Invest Ophthalmol Vis Sci 2007 (Anoxia...) : Inhibition of MEK1 by pharmacologic and dominant negative mutant approaches attenuated 15 ( S ) -HETE induced phosphorylation of ERK1/2 and JNK1 but not p38 MAPK
Park et al., Mol Cancer Ther 2008 (Carcinoma, Hepatocellular...) : Inhibition of p38 MAPK or knockdown of BID, FAS associated death domain, or CD95 expression suppressed MEK1/2 inhibitor and 17AAG lethality
Aroor et al., Alcohol 2009 : These results suggest that Ang II-mediated accumulation of phospho-p42/44 MAPK in the hepatocyte nucleus involves MEK 1/2 dependent activation and this effect is potentiated by ethanol
Tartaglia et al., Molecular syndromology 2010 : SHP2 ( encoded by PTPN11 ), SOS1, BRAF, RAF1 and MEK1 positively contribute to RAS-MAPK signaling, and possess complex autoinhibitory mechanisms that are impaired by mutations
Pike et al., Cell Signal 2013 : Truncated MEK1 is required for transient activation of MAPK signalling in G2 phase cells
Huwiler et al., Br J Pharmacol 1994 : 2. Both nucleotides stimulate phosphorylation and activation of mitogen activated protein kinase and a biphasic phosphorylation of the up-stream mitogen activated protein kinase kinase
Gardner et al., Mol Biol Cell 1994 : Raf and MAPK/extracellular signal regulated kinase kinase ( MEKK ) independently phosphorylate and activate MEK-1
Gardner et al., J Biol Chem 1996 : Pharmacological inhibition of MEK-1 activity by incubation of cells with the compound PD 098059 blocked p42(MAPK) activation and FGF-2 protection against apoptosis
Ho et al., J Neurochem 1997 : Mobility shift, phosphoepitope analysis, and direct measurement of kinase activity indicated that the Mek1 inhibitor dose-dependently blocked basal and okadaic acid induced MAPK activation
Bazan et al., Curr Eye Res 1997 : Corneal tissue expresses ERK2 or MAPK, and both MEK1 and MEK2, the immediate upstream regulators of MAPK
Nantel et al., J Biol Chem 1998 : Interaction of Grb10 with Raf1 is constitutive, while interaction between Grb10 and MEK1 needs insulin treatment of the cells and follows mitogen activated protein kinase activation
Daum et al., FEBS Lett 1998 : Pervanadate inhibits mitogen activated protein kinase kinase-1 in a p38MAPK dependent manner
Denis-Henriot et al., Endocrinology 1998 : Wild-type Galpha12 overexpression prevented the decrease in MAPK activity and induced MEK1 , but not B-Raf, expression
Tsatsanis et al., Oncogene 1998 (Lymphoma, T-Cell) : Since the activation of NFAT is MAPK dependent these findings suggested that the activation of MAPK by Tpl-2 is either independent or only partially dependent on MEK1 and MEK2